Announced Sat, 26 Sept, 2026 · 20:16 IST
Aarti Drugs AGM: FY26 PAT up 3% at Rs 312 cr; Q1 FY27 revenue up 19%
Mgmt Guided Margin ImprovementOrder Pipeline DisclosedInvestor Communications View source PDFExplain this filing
AARTIDRUGS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+0.4%1-day move
₹426.10
prior close
₹430.85
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.4+0.3+0.2+1.2+0.4+1.4-1.7-2.7+0.6-1.9————
Up moveDown movePending
AI summary
Aarti Drugs FY26 revenue Rs 2,568 cr (+7%), EBITDA Rs 195 cr (+16%), PAT Rs 312 cr (+3%). Q1 FY27: revenue Rs 704 cr (+19%), EBITDA Rs 69 cr (+35%). Rs 600 cr capex done; Sayakha methylamines plant commissioned for backward integration. Rs 200 cr invested in oncology with USFDA approval. Metformin capacity scaling to 2,800 TPM; anti-inflammatory facility targeting Rs 35-50 cr. Around 330 regulatory filings across 16 geographies.
Likely market impact
Strong Q1 FY27 growth (revenue +19%, EBITDA +35%) signals margin recovery. USFDA approvals and oncology expansion should support better returns.